公开(公告)号：US11026916B2

公开(公告)日：2021-06-08

申请号：US16453934

申请日：2019-06-26

Applicant: DSM IP ASSETS B.V.

Inventor： Szabolcs Peter ,  Joseph Schwager

IPC: A61K31/355 ,  A61K31/202 ,  A23L33/12 ,  A23L33/15 ,  A61P1/16 ,  A61K31/22

Abstract: Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.

公开(公告)号：US20140296190A1

公开(公告)日：2014-10-02

申请号：US13851463

申请日：2013-03-27

Applicant: DSM IP ASSETS B.V.

Inventor： Elske Maria BROUWER-BROLSMA ,  Edith Johanna Maria Feskens ,  Lisette CPGM De Groot ,  Stephanie J.M. Krammer-Lukas ,  Hasan Mohajeri ,  Szabolcs Peter ,  Jonas Wittwer Schegg

IPC: A61K31/593

CPC classification number: A61K31/593 ,  A23L33/155 ,  A23V2002/00 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/7106

Abstract: This invention relates to a method of marketing 25-hydroxyvitamin D3 (25-OH D3) comprising providing an effective dose of 25-OH D3 and informing the potential consumer that it is beneficial for increasing or maintaining executive functioning, or lessening the decrease of cognitive functioning. Kits containing the 25-OH D3 and information regarding its benefits in this area are also part of this invention.

Abstract translation: 本发明涉及营销25-羟基维生素D 3（25-OH D3）的方法，其包括提供有效剂量的25-OH D3并通知潜在消费者有利于增加或维持执行功能，或减轻认知的减少 功能。 含有25-OH D3的试剂盒及其在该领域的益处的信息也是本发明的一部分。

公开(公告)号：US10682334B2

公开(公告)日：2020-06-16

申请号：US16166357

申请日：2018-10-22

Applicant: DSM IP ASSETS B.V.

Inventor： Szabolcs Peter ,  Joseph Schwager ,  Weerasinghe M. Indrasena ,  Jaroslav A. Kralovec ,  Bernd Mussler

IPC: A61K31/355 ,  A61P1/16 ,  A61K31/22

Abstract: The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

公开(公告)号：US09707242B2

公开(公告)日：2017-07-18

申请号：US14780299

申请日：2014-03-27

Applicant: DSM IP ASSETS B.V.

Inventor： Elske Maria Brouwer-Brolsma ,  Edith Johanna Maria Feskens ,  Lisette De Groot ,  Stephanie J. M. Krammer-Lukas ,  Hasan Mohajeri ,  Szabolcs Peter ,  Jonas Witter-Schegg

IPC: A61K31/593 ,  A61K9/00 ,  A23L33/155

CPC classification number: A61K31/593 ,  A23L33/155 ,  A23V2002/00 ,  A61K9/0053 ,  A23V2200/322 ,  A23V2250/71 ,  A23V2250/7106 ,  A61K2300/00

Abstract: This invention relates to the use of 25-hydroxyvitamin D3 (25-OH D3) to increase or maintain or alternatively, to lessen the decrease of the cognitive element known as executive functioning in healthy individuals. Optionally, 25-OH D3 may be administered in combination with Vitamin D or other ingredients.